Credit score: Unsplash/CC0 Public Area
Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed to deal with kind 2 diabetes, have important heart- and kidney- protecting results.
Within the kidney, SGLT2 reabsorbs roughly 97% of filtered glucose within the S1 and S2 segments of the proximal tubule, whereas SGLT1 reabsorbs the rest within the S3 section. In analysis carried out in rats, investigators discovered that twin inhibition of SGLT1 and SGLT2 extra successfully reduces salt-sensitive hypertension and kidney harm than SGLT2 inhibition alone. The findings might be offered at ASN Kidney Week 2025 from November 5–9.
Salt-sensitive hypertension—elevated blood strain because of extra salt consumption—impacts almost half of people with hypertension and considerably contributes to kidney illness, cardiovascular problems, and development to kidney failure.
When researchers in contrast selective SGLT2 inhibition (by way of remedy with dapagliflozin) with twin SGLT1/2 inhibition (by way of remedy with sotagliflozin) in a well-established rat mannequin of salt-induced hypertension and persistent kidney illness, they discovered that each medication had profound results on slowing the development of salt-induced hypertension.
In contrast with selective SGLT2 inhibition, twin SGLT1/2 inhibition produced a better discount in imply arterial strain and extra successfully attenuated kidney harm, though it had no affect on blood strain beneath normal-salt situations. Sotagliflozin additionally decreased physique weight, enhanced urinary sodium and chloride excretion, and almost doubled fractional glucose excretion in contrast with dapagliflozin.
Neither remedy altered kidney perform. SGLT2 inhibition modulated a number of metabolic pathways in a region-specific method within the kidney, with pronounced results on lipid metabolism and inflammatory signaling.
“Our study provides preclinical evidence supporting the expanded use of dual SGLT1/2 inhibitors beyond heart failure and diabetes, extending their potential into hypertension management, particularly in salt-sensitive patients,” stated corresponding writer Olha Kravtsova, Ph.D., of the College of South Florida.
“These findings also establish a foundation for further investigation into regional kidney metabolism. Moreover, they highlight lipid and inflammatory pathways as promising therapeutic targets in the treatment of hypertension.”
Extra data:
Examine: Twin SGLT1/2 inhibition attenuates salt-sensitive hypertension and kidney harm extra successfully than SGLT2 inhibition (2025)
Supplied by
American Society of Nephrology
Quotation:
Sotagliflozin outperforms dapagliflozin for decreasing salt- delicate hypertension and kidney harm in rats (2025, November 7)
retrieved 8 November 2025
from https://medicalxpress.com/information/2025-11-sotagliflozin-outperforms-dapagliflozin-salt-sensitive.html
This doc is topic to copyright. Aside from any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for data functions solely.
